19743-76-1

Basic information

• Product Name: 1H-Pyrazolo[3,4-b]pyridine-5-carboxylic acid, 4-chloro-1-phenyl-, ethyl ester
• CAS NO: 19743-76-1
• Molecular Formula: C15H12ClN3O2
• Molecular Weight: 301.732
• Mol File: 19743-76-1.mol
• Article Data: 13

Chemical Properties

• CAS DataBase Reference: 1H-Pyrazolo[3,4-b]pyridine-5-carboxylic acid, 4-chloro-1-phenyl-, ethyl ester(CAS DataBase Reference)
• NIST Chemistry Reference: 1H-Pyrazolo[3,4-b]pyridine-5-carboxylic acid, 4-chloro-1-phenyl-, ethyl ester(19743-76-1)
• EPA Substance Registry System: 1H-Pyrazolo[3,4-b]pyridine-5-carboxylic acid, 4-chloro-1-phenyl-, ethyl ester(19743-76-1)

Safety Data

• Hazardous Substances Data: 19743-76-1(Hazardous Substances Data)

Usage

Molecular structure

1H-Pyrazolo[3,4-b]pyridine-5-carboxylic acid, 4-chloro-1-phenyl-, ethyl ester is a heterocyclic compound that contains a pyrazolo[3,4-b]pyridine ring with a 4-chloro-1-phenyl group and an ethyl ester functional group attached to it.

Molecular weight

330.76 g/mol

Appearance

It is likely a solid with a specific color that can vary depending on the synthesis method and purity.

Solubility

It may be soluble in common organic solvents such as DMSO, methanol, or ethanol, but its solubility can vary depending on the specific conditions.

Stability

The compound may be stable under standard temperature and pressure conditions, but it may be sensitive to light, heat, or moisture.

Biological activity

As a derivative of pyrazolo[3,4-b]pyridine, this compound may exhibit potential biological and pharmacological activities. Its 4-chloro-1-phenyl group and ethyl ester functional group may contribute to its interactions with biological targets.

Applications

The compound may be used in drug discovery and development, as well as in the study of organic chemistry and chemical biology.

Synthesis

The synthesis of this compound may involve various chemical reactions and techniques, including the formation of the pyrazolo[3,4-b]pyridine ring and the attachment of the 4-chloro-1-phenyl and ethyl ester groups.

Safety

As with any chemical compound, appropriate safety precautions should be taken when handling 1H-Pyrazolo[3,4-b]pyridine-5-carboxylic acid, 4-chloro-1-phenyl-, ethyl ester, including the use of personal protective equipment and proper disposal of waste materials.

Upstream product

• 19743-75-0 4-oxo-1-phenyl-4,7-dihydro-1H-pyrazolo[3,4-b]pyridine-5-carboxylic acid ethyl ester 
• 62-53-3 aniline 
• 826-85-7 1-phenylpyrazol-5-amine 
• 37555-99-0 diethyl ethoxymalonate 
• 87-13-8 diethyl 2-ethoxymethylenemalonate 
• 37799-81-8 diethyl{[(1-phenyl-5-pyrazolyl)-amino]methylene} malonate 
• 54844-13-2 carbethoxy-5 dihydro-3,6 oxo-6 phenyl-2 pyrazolo <2,4-b> pyridine 

Downstream Products

• 1031442-71-3 ethyl 4-(3'-chlorophenylamino)-1-phenyl-1H-pyrazolo[3,4-b]pyridine-5-carboxylate 
• 1049619-85-3 C₂₀H₂₂N₄O₃ 
• 1031442-98-4 4-[(4-methylpyridin-2-yl)amino]-1-phenyl-1H-pyrazolo[3,4-b]pyridine-5-carboxylic acid 

Relevant articles and documents

Deciphering the robustness of pyrazolo-pyridine carboxylate core structure-based compounds for inhibiting α-synuclein in transgenic C. elegans model of Synucleinopathy

Parkinson's disease (PD), a calamitous neurodegenerative disorder with no cure till date, is closely allied with the misfolding and aggregation of α-Synuclein (α -Syn). Inhibition of α-Syn aggregation is one of the optimistic approaches for the treatment for PD. Here, we carried out hypothesis-driven studies towards synthesising a series of pyrazolo-pyridine carboxylate containing compounds (7a–7m) targeted at reducing deleterious α-Syn aggregation. The target compounds were synthesized through multi-step organic synthesis reactions. From docking studies, compounds 7b, 7g and 7i displayed better interaction with the key residues of α-Syn with values: ?6.8, ?8.9 and ?7.2 Kcal/mol, respectively. In vivo transgenic C. elegans model of Synucleinopathy was used to evaluate the ability of the designed and synthesized compounds to inhibit α-Syn aggregation. These lead compounds 7b, 7g and 7i displayed 1.7, 2.4 and 1.5-fold inhibition of α-Syn with respect to the control. Further, the strategy of employing pyrazolo-pyridine-based compounds worked with success and these scaffolds could be further modified and validated for betterment of endpoints associated with PD.

Design, synthesis and anti-P. falciparum activity of pyrazolopyridine–sulfonamide derivatives

Ten 1-phenyl-1H-pyrazolo[3,4-b]pyridine derivatives connected by a linker group to benzenesulfonamide moieties with different substituents in the 4-position were synthesized and assayed against Plasmodium falciparum. These ten compounds exhibited activity in vitro against the chloroquine-resistant clone W2 with IC50values ranging from 3.46 to 9.30 μM. The most active derivatives with substituent R2= Cl or CH3at the benzenesulfonamide moiety exhibited the lowest IC50. Compounds with an R1= CO2Et substituent at the 5-position of the 1H-pyrazolo[3,4-b]pyridine ring presented lower activity than those with a CN substituent. The 1H-pyrazolo[3,4-b]pyridine system appears to be promising for further studies as an antimalarial for overcoming the burden of resistance in P. falciparum.

Mass spectrometry of pyrazolo[3,4-b]pyrido[2′,3′-b]-1,6-naphthyridines and dipyrazolo[3,4-b];3′,4′-h]-1,6-naphthyridines

The mass spectra of several pyrazolo[3,4-b]pyrido[2′,3′-b]-1,6-naphthyridines and dipyrazolo[3,4-b];3′,4′-h]-1,6-naphthyridines are presented. The fragmentation is initiated by the elimination of CO molecule [m/z 28] followed by other fragments, such as h